Light Chain Bioscience (Novimmune)
VerifiedDevelops therapeutic monoclonal antibodies to treat patients suffering from immune-related disorders
Launch date
Employees
Ownership
Firm valuation
$119—178m (Dealroom.co estimates Jan 2016.)
Geneva Canton of Geneva (HQ)
Financials
Edit| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - Not yet verified | |
| $14m | Series A | ||
| $46m | Series B | ||
| N/A | N/A | Early VC Not yet verified | |
| $54.8m | Series C | ||
| N/A | $22.4m | Series D | |
| N/A | N/A | Early VC Not yet verified | |
| N/A | €6m | Grant | |
| $66m | Series E | ||
* | €27m | Series F | |
| Total Funding | $240m | ||
Recent News about Light Chain Bioscience (Novimmune)
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.